While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

E ver since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Mounjaro, manufactured by US drugmaker, and Wegovy by Danish drugmaker Novo Nordisk, cause weight loss by suppressing the ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...

More than three-quarters of patients taking both drugs reported at least one side effect, mostly mild to moderate ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...